Free Trial

BioRem (CVE:BRM) Reaches New 12-Month High - What's Next?

BioRem logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

  • 52-week high: BioRem (CVE:BRM) reached a new 52-week high of C$3.41, up about 1.2% on the day with 21,035 shares traded.
  • Technical and valuation signals show an uptrend (50-day SMA C$2.66 vs. 200-day SMA C$2.52) with a market cap of C$55.02 million and a P/E of 13.12.
  • BioRem is a clean‑technology company supplying air pollution control systems (biofilters, biotrickling filters, biogas desulfurization, cannabis odor control), and its balance sheet shows a current ratio of 1.85, quick ratio 1.08 and debt‑to‑equity of 18.97.
  • MarketBeat previews the top five stocks to own by June 1st.

BioRem Inc. (CVE:BRM - Get Free Report)'s stock price hit a new 52-week high on Thursday . The company traded as high as C$3.41 and last traded at C$3.41, with a volume of 21035 shares. The stock had previously closed at C$3.37.

BioRem Stock Up 1.2%

The business has a 50-day simple moving average of C$2.66 and a two-hundred day simple moving average of C$2.52. The company has a market cap of C$55.02 million, a price-to-earnings ratio of 13.12 and a beta of 1.05. The company has a quick ratio of 1.08, a current ratio of 1.85 and a debt-to-equity ratio of 18.97.

About BioRem

(Get Free Report)

BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioRem Right Now?

Before you consider BioRem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioRem wasn't on the list.

While BioRem currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines